Table 1.
Demographic features, clinical and laboratory manifestations and treatments in152 patients with SLE
| Value | |
|---|---|
| Clinical manifestations – N (%) | |
| Skin involvement | 115 (75.7) |
| Serositis | 31 (20.4) |
| Hematological manifestations | 99 (65.1) |
| Neuropsychiatric involvement | 15 (9.9) |
| Renal involvement | 33 (21.7) |
| Laboratory manifestations – N (%) | |
| Anti-dsDNA | 114 (78.9) |
| Anti-Sm | 28 (18.4) |
| Anti-SSA | 62 (40.8) |
| Anti-SSB | 35 (23.0) |
| Anti-RNP | 24 (15.8) |
| Anti-cardiolipin IgG/IgM | 44 (28.9) |
| Anti-β2GPI IgG/IgM | 38 (25.0) |
| Lupus anticoagulant | 39 (25.6) |
| Low C3/C4 levels | 81 (53.3) |
| Treatments – N (%) | |
| Glucocorticoids | 140 (92.1) |
| Hydroxychloroquine | 144 (94.7) |
| Cyclosporine A | 34 (22.4) |
| Methotrexate | 59 (38.8) |
| Cyclophosphamide | 6 (3.9) |
| Mycophenolate mofetil | 43 (28.3) |
| Azathioprine | 29 (19.1) |
| Rituximab | 4 (2.6) |
| Belimumab | 9 (5.9) |
SLE systemic lupus erythematosus